Yahoo Finance Today’s Research Reports on Trending Tickers: Acorda Therapeutics and BioCryst Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / January 22, 2018 / U.S. markets rebounded on Friday, posting a weekly gain, as positive earnings outweighed worries of a government shutdown. The Dow Jones Industrial Average was up 0.21 percent to close at 26,071.72, while the S&P 500 Index increased 0.44 percent to close at 2,810.30. The Nasdaq Composite Index gained 0.55 percent to close at 7,336.38. Both the Dow Jones and Nasdaq rose approximately 1 percent for the week, while the S&P 500 recorded 0.9 percent gain.
"I would characterize a shutdown as just the kind of political news that the market has demonstrated, over the past year, a willingness to ignore," said Hank Smith, co-chief investment officer at Haverford Trust. According to Smith, "the market is reacting to GDP growth both here and abroad; corporate profits, which are growing by double-digit rates and are healthy; interest rates that remain low despite a gradual uptick; and benign inflation."
RDI Initiates Coverage on:
Acorda Therapeutics, Inc.
https://rdinvesting.com/news/?ticker=ACOR
BioCryst Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=BCRX
Acorda Therapeutics stock jumped 8.80% Friday, to close the day at $27.20. The stock recorded a trading volume of 3,988,062 shares, which was above its three months average volume of 878,086 shares. In the last year, Acorda Therapeutics shares have traded in a range of 13.60 - 33.00. The share price has gained 100.00% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $22.35 is below its 200-day moving average of $22.96. Shares of Acorda Therapeutics have gained roughly 25.06 percent in the past month and are up 26.81 percent year-to-date.
Access RDI's Acorda Therapeutics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ACOR
On Friday, shares of BioCryst Pharmaceuticals recorded a trading volume of 720,269 shares, which was below the three months average volume of 1,072,580 shares. The stock ended the day 1.58% lower at 5.59. The share price has gained 41.52% from its 52 week low with a 52 week trading range of 3.95 - 9.25.The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $5.22 is greater than its 200-day moving average of $5.04. Shares of BioCryst Pharmaceuticals have gained roughly 11.8 percent in the past month and are up 13.85 percent year-to-date.
Access RDI's BioCryst Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=BCRX
Our Actionable Research on Acorda Therapeutics, Inc. (NASDAQ :ACOR) and BioCryst Pharmaceuticals, Inc. (NASDAQ :BCRX) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
